MAPT and early-onset autosomal dominant Alzheimer disease: Currently, PROTAC technology offers the possibility of inhibiting Tau aggregation by inducing dephosphorylation (42), holding promise as a therapeutic approach for Alzheimer’s disease and other neurodegenerative disorders.